Additional file 1 of Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis
Creators: name: Yan, Wu
name: Chen, Danrong
name: Bigambo, Francis Manyori
name: Wei, Hongcheng
name: Wang, Xu
name: Xia, Yankai
Publisher: name: figshare
Year: 2021
Subjects: subject: Immunology
subject: FOS: Clinical medicine

description: Additional file 1: Table S1 PRISMA checklist. Table S2 Search strategies. Table S3 Characteristics of the articles included in our meta-analysis. Fig. S1 Forest maps of white blood cell (WBC) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S2 Forest maps of lymphocyte (LYM) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S3 Forest maps of neutrophil (NEUT) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S4 Forest maps of monocytes (MONO) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S5 Forest maps of platelet (PLT) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S6 Forest maps of hemoglobin (HB) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S7 Forest maps of cluster of differentiation 3 (CD3+) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S8 Forest maps of cluster of differentiation 4 (CD4+) comparison in COVID-19 patients with different clinical stages: *represents statistically significant differences (P &lt; 0.05). Fig. S9 Forest maps of cluster of differentiation 8 (CD8+) comparison in COVID-19 patients with different clinical stages: *represents statistically significant differences (P &lt; 0.05). Fig. S10 Forest maps of cluster of differentiation 19 (CD19+) comparison in COVID-19 patients with different clinical stages: *represents statistically significant differences (P &lt; 0.05). Fig. S11 Forest maps of cluster of differentiation 16+ 56+ (CD16+ CD56+) comparison in COVID-19 patients with different clinical stages: *represents statistically significant differences (P &lt; 0.05). Fig. S12 Forest maps of interlcukin-1β (IL-1β) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S13 Forest maps of interlcukin-6 (IL-6) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S14 Forest maps of interlcukin-10 (IL-10) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S15 Forest maps of tumor necrosis factor-α (TNF-α) comparison in COVID-19 patients with different clinical stages. * represents statistically significant differences (P &lt; 0.05). Fig. S16 Funnel plot, WBC. Fig. S17 Funnel plot, LYM. Fig. S18 Funnel plot, NEUT. Fig. S19 Funnel plot, MONO. Fig. S20 Funnel plot, PLT. Fig. S21 Funnel plot, HB. Fig. S22 Funnel plot, CD3+. Fig. S23 Funnel plot, CD4+. Fig. S24 Funnel plot, CD8+. Fig. S25 Funnel plot, CD19+. Fig. S26 Funnel plot, CD16+ CD56+. Fig. S27 Funnel plot, IL-1β. Fig. S28 Funnel plot, IL-6. Fig. S29 Funnel plot, IL-10. Fig. S30 Funnel plot, TNF-α. Table S4 Subgroup analysis of immune-inflammatory parameters in COVID-19 patients with different clinical types. Table S5 Comparison of direct, indirect, and network meta-analyses results.